-
公开(公告)号:US6020336A
公开(公告)日:2000-02-01
申请号:US146009
申请日:1998-09-02
申请人: Gilbert Lavielle , Olivier Muller , Christine Vayssettes-Courchay , Jean-Jacques Descombes , Tony Verbeuren
发明人: Gilbert Lavielle , Olivier Muller , Christine Vayssettes-Courchay , Jean-Jacques Descombes , Tony Verbeuren
IPC分类号: C07D401/14 , A61K31/41 , A61K31/415 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/495 , A61K31/505 , A61P9/00 , A61P9/12 , A61P25/04 , A61P25/06 , A61P43/00 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D521/00 , A61K31/425 , C07D403/10
CPC分类号: C07D231/12 , C07D233/56 , C07D249/08
摘要: Compound of formula (I): ##STR1## wherein: n is 0 or 1,A represents a .sigma. bond or alkylene or alkenylene,X represents nitrogen or C--R.sub.2,R.sub.1 represents hydrogen or alkyl, andG.sub.1 represents any one of the groups defined in the description and medicaments containing the same.
摘要翻译: 式(I)化合物:其中:n为0或1,A表示σ键或亚烷基或亚烯基,X表示氮或C-R2,R1表示氢或烷基,G1表示 描述和含有相同的药物。
-
公开(公告)号:US6046205A
公开(公告)日:2000-04-04
申请号:US299314
申请日:1999-04-26
申请人: Gilbert Lavielle , Olivier Muller , Christine Vayssettes-Courchay , Jean-Jacques Descombes , Tony Verbeuren
发明人: Gilbert Lavielle , Olivier Muller , Christine Vayssettes-Courchay , Jean-Jacques Descombes , Tony Verbeuren
IPC分类号: C07D401/14 , A61K31/41 , A61K31/415 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/495 , A61K31/505 , A61P9/00 , A61P9/12 , A61P25/04 , A61P25/06 , A61P43/00 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D521/00
CPC分类号: C07D231/12 , C07D233/56 , C07D249/08
摘要: Compound of formula (I): ##STR1## wherein: n is 0 or 1,A represents a .sigma. bond or alkylene or alkenylene,X represents nitrogen or C--R.sub.2,R.sub.1 represents hydrogen or alkyl,G.sub.1 represents any one of the groups defined in the description.These compounds are useful for treating a living body afflicted with venous insufficiency, and/or migraine, and/or migraine associated with vascular diseases.
摘要翻译: 式(I)化合物:其中:n为0或1,A表示σ键或亚烷基或亚烯基,X表示氮或C-R2,R1表示氢或烷基,G1表示说明书中定义的任何一个基团 。 这些化合物可用于治疗患有静脉功能不全的活体,和/或偏头痛,和/或与血管疾病相关的偏头痛。
-
公开(公告)号:US5472979A
公开(公告)日:1995-12-05
申请号:US323508
申请日:1994-10-14
申请人: Gilbert Lavielle , Thierry Dubuffet , Olivier Muller , Michel Laubie , Tony Verbeuren , Serge Simonet , Jean-Jacques Descombes
发明人: Gilbert Lavielle , Thierry Dubuffet , Olivier Muller , Michel Laubie , Tony Verbeuren , Serge Simonet , Jean-Jacques Descombes
IPC分类号: A61K31/18 , A61K31/35 , A61K31/352 , A61K31/38 , A61K31/382 , A61P7/02 , A61P9/00 , A61P43/00 , C07C311/02 , C07C311/14 , C07C311/20 , C07C311/29 , C07D213/55 , C07D311/58 , C07D335/06 , A61K31/14
CPC分类号: C07D335/06 , C07C311/20 , C07D213/55 , C07D311/58
摘要: R.sub.1 and R.sub.2 form, with the carbon atoms to which they are attached, cyclopentane or cyclohexane,R.sub.3 represents hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy or unsubstituted or substituted amino,R.sub.4 represents alkyl, unsubstituted or substituted phenyl, naphthyl, pyridyl or thienyl, X represents methylene or oxygen or sulfur,its enantiomers and its addition salts with a pharmaceutically acceptable base, and medicinal products containing the same are useful as anti-thrombotic.
摘要翻译: 其中:R 1和R 2可以相同或不同,表示氢或卤素,烷基,取代或未取代的苯基,苄基,吡啶基甲基或咪唑基甲基或噻唑基甲基,吡啶基,咪唑基或噻唑基,或者R1 和R 2与它们所连接的碳原子形成环戊烷或环己烷,R 3表示羟基,直链或支链(C 1 -C 6)烷氧基或未取代或取代的氨基,R 4表示烷基,未取代或取代的苯基,萘基,吡啶基或 噻吩基,X表示亚甲基或氧或硫,其对映体及其与药学上可接受的碱的加成盐,以及含有它们的药物可用作抗血栓形成。
-
公开(公告)号:US5348968A
公开(公告)日:1994-09-20
申请号:US189798
申请日:1994-02-01
申请人: Gilbert Lavielle , Philippe Maillos , Olivier Muller , Michel Laubie , Tony Verbeuren , Jean-Jacques Descombes
发明人: Gilbert Lavielle , Philippe Maillos , Olivier Muller , Michel Laubie , Tony Verbeuren , Jean-Jacques Descombes
IPC分类号: A61K31/40 , A61K31/415 , A61P25/04 , C07D403/06 , C07D403/14 , C07D413/06 , C07D413/14 , C07D419/14 , A61K31/41 , C07D209/08 , C07D231/56
CPC分类号: C07D403/06 , C07D403/14 , C07D413/06 , C07D413/14 , C07D419/14
摘要: The invention relates to a compound of formula (I): ##STR1## in which: R.sub.1 represents hydrogen or halogen, alkyl, alkoxy, cyano or aminocarbonyl or any one of the following: ##STR2## in which: m is equal to 1, 2 or 3,n is equal to 0, 1 or 2,T represents a CO or SO.sub.2,R.sub.4 or R.sub.5, which are identical or different, represent hydrogen or alkyl or phenyl,R.sub.2 represents hydrogen or alkyl, phenyl or acyl,R.sub.3 represents hydrogen, alkyl (optionally substituted by hydroxyl or phenyl) or alkoxycarbonyl,--X--Y.dbd. represents --N--C.dbd., --N--N.dbd.or else ##STR3## represents --O--N.dbd.; to its enantiomers, diastereoisomers and epimers and to its addition salts with a pharmaceutically acceptable acid.
摘要翻译: 本发明涉及式(I)化合物:其中:R 1表示氢或卤素,烷基,烷氧基,氰基或氨基羰基或下列任何一种:(CH 2) mNHCONHR4,
(CH2)mSO2NHR4,CHCHSO2NHR4, 其中:m等于1,2或3,n等于0,1或2,T表示CO或SO2 ,R 4或R 5相同或不同,表示氢或烷基或苯基,R 2表示氢或烷基,苯基或酰基,R 3表示氢,烷基(任选被羟基或苯基取代)或烷氧基羰基,-XY =表示-NC =,-NN =否则 表示-ON =; 其对映异构体,非对映异构体和差向异构体及其与药学上可接受的酸的加成盐。 -
5.
公开(公告)号:US5407946A
公开(公告)日:1995-04-18
申请号:US259697
申请日:1994-06-14
IPC分类号: A61K31/40 , A61K31/44 , A61K31/4427 , A61K31/47 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00 , C07D207/08 , C07D207/22 , C07D207/48 , C07D401/04 , C07D401/06 , C07D401/12
CPC分类号: C07D401/06 , C07D207/22 , C07D207/48 , C07D401/12
摘要: Components of formula (I): ##STR1## in which: R.sub.1 represents optionally substituted phenylsulfonyl, naphthylsulfonyl, quinolyl, or isoquinolyl,R.sub.2 represents hydrogen, optionally substituted phenyl, or optionally substituted 3-pyridyl or 2-pyridyl,R.sub.3 represents ##STR2## in which m is equal to 2, 3, or 4; n is equal to 4, 5, 6, or 7; and R represents hydrogen or alkyl, as thromboxane A.sub.2 receptor inhibitors or thromboxane A.sub.2 -synthase inhibitors, and pharmaceutical compositions containing the same.
摘要翻译: 式(I)的组分:其中:R 1表示任选取代的苯磺酰基,萘磺酰基,喹啉基或异喹啉基,R 2表示氢,任选取代的苯基或任选取代的3-吡啶基或2-吡啶基,R 3表示 或者(CH2)nCO2R,其中m等于2,3或4; n等于4,5,6或7; 和R表示氢或烷基,作为凝血恶烷A2受体抑制剂或血栓烷A2-合成酶抑制剂,以及含有它们的药物组合物。
-
公开(公告)号:US5387591A
公开(公告)日:1995-02-07
申请号:US16501
申请日:1993-02-11
IPC分类号: A61K31/40 , A61K31/44 , A61K31/4427 , A61K31/47 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00 , C07D207/08 , C07D207/22 , C07D207/48 , C07D401/04 , C07D401/06 , C07D401/12
CPC分类号: C07D401/06 , C07D207/22 , C07D207/48 , C07D401/12
摘要: Compounds of formula (I): ##STR1## in which: R.sub.1 represents:optionally substituted alkyl,optionally substituted phenyl,pyridyl,optionally substituted phenylsulfonyl,acyl,optionally substituted benzoyl or pyridylcarbonyl,alkylaminocarbonyl or phenylaminocarbonyl,acylamino or benzoylamino,R2 represents:hydrogen,optionally substituted phenyl,optionally substituted 3-pyridyl or 2-pyridyl,R.sub.3 represents any one of the following groups: ##STR2## in which m is equal to 2, 3 or 4,n is equal to 4, 5, 6 or 7, and R represents hydrogen or alkyl.
摘要翻译: 式(I)化合物:其中:R1表示:任选取代的烷基,任选取代的苯基,吡啶基,任选取代的苯基磺酰基,酰基,任选取代的苯甲酰基或吡啶基羰基,烷基氨基羰基或苯基氨基羰基,酰基氨基或苯甲酰基氨基,R2 表示:氢,任选取代的苯基,任选取代的3-吡啶基或2-吡啶基,R 3表示以下基团中的任何一个:其中m等于2,3或4,n(CH 2)n CO 2 R 等于4,5,6或7,R代表氢或烷基。
-
公开(公告)号:US07053108B2
公开(公告)日:2006-05-30
申请号:US10813347
申请日:2004-03-30
申请人: Gilbert Lavielle , Olivier Muller , Mark Millan , Alain Gobert
发明人: Gilbert Lavielle , Olivier Muller , Mark Millan , Alain Gobert
IPC分类号: A61K31/443 , C07D401/12
CPC分类号: C07D401/12
摘要: A compound of formula (I): wherein: R1 and R2 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 represents hydrogen,orR1 represents hydrogen, and R2 and R3 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicaments.
摘要翻译: 式(I)化合物:其中:R 1和R 2一起形成任选被卤素取代的苯并环,或烷基,烷氧基,氰基,硝基,羟基, 氨基,烷基氨基,二烷基氨基或三氟甲基,R 3表示氢,或R 1表示氢,R 2和R 3 硝基,羟基,氨基,烷基氨基,二烷基氨基或三氟甲基,其对映异构体,非对映异构体及其与药学上可接受的酸或碱的加成盐共同形成任选被卤素取代的苯并环, 和药物。
-
公开(公告)号:US5500443A
公开(公告)日:1996-03-19
申请号:US392203
申请日:1995-02-22
IPC分类号: C07D319/16 , A61K31/00 , A61K31/335 , A61K31/357 , A61K31/40 , A61K31/4025 , A61K31/443 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/453 , A61K31/55 , A61P25/18 , A61P25/22 , C07D319/18 , C07D319/20 , C07D405/12 , C07D405/14 , C07D413/14 , C07D207/04
CPC分类号: C07D405/12 , C07D319/18 , C07D319/20 , C07D405/14 , C07D413/14
摘要: A compound of formula (I): ##STR1## in which: X represents oxygen or methylene,n represents 1, 2 or 3,R.sub.1 represents hydrogen, aminocarbonyl or hydroxymethyl,R.sub.2 represents: ##STR2## in which R.sub.3 and R.sub.4 are as defined in the description, the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful in the treatment of schizophrenia.
摘要翻译: 式(I)的化合物:其中:X表示氧或亚甲基,n表示1,2或3,R1表示氢,氨基羰基或羟甲基,R2表示:其中R3和R4 如本说明书中所定义,其异构体及其与药学上可接受的酸或碱的加成盐,以及含有它们的药物可用于治疗精神分裂症。
-
公开(公告)号:US07026357B2
公开(公告)日:2006-04-11
申请号:US10862546
申请日:2004-06-07
IPC分类号: A61K31/17 , C07D233/02 , C07D401/00 , C07D211/70 , C07C273/00
CPC分类号: C07D295/135 , C07D209/08 , C07D235/14 , C07D235/30 , C07D319/20 , C07D401/04 , C07D405/04 , C07D405/12
摘要: Compound of formula (I): and medicinal products containing the same are useful as dual α2/5-HT2c antagonist receptors.
摘要翻译: 式(I)化合物:含有该化合物的药物可用作双重α2/5-HT 2C拮抗剂受体。
-
公开(公告)号:US06747032B2
公开(公告)日:2004-06-08
申请号:US10125188
申请日:2002-04-18
申请人: Gilbert Lavielle , Thierry Dubuffet , Olivier Muller , Mark Millan , Anne Dekeyne , Mauricette Brocco
发明人: Gilbert Lavielle , Thierry Dubuffet , Olivier Muller , Mark Millan , Anne Dekeyne , Mauricette Brocco
IPC分类号: C07D51900
CPC分类号: C07D471/04
摘要: Compound of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen atom, a halogen atom or a group selected from alkyl, alkoxy, polyhaloalkyl, hydroxy, cyano, nitro and amino, or R1 with R2, R2 with R3, or R3 with R4, together with the carbon atoms carrying them, form an optionally substituted benzene ring or an optionally substituted heteroaromatic ring, X represents an oxygen atom or a methylene group, A represents an alkylene chain, represents an optionally substituted, unsaturated, nitrogen-containing heterocycle and R5 represents an alkyl group, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid, a medicinal products containing the same are useful as a double &agr;2/5-HT2c antagonist.
摘要翻译: 式(I)化合物:其中:R 1,R 2,R 3和R 4可以相同或不同,表示氢原子,卤素原子或选自烷基,烷氧基,多卤代烷基,羟基,氰基,硝基 和氨基,或R 1与R 2,R 2与R 3或R 3与R 4一起形成任选取代的苯环或任选取代的杂芳环,X表示氧原子或亚甲基,A表示 亚烷基链表示任选取代的不饱和的含氮杂环,R5表示烷基,其对映异构体和非对映异构体及其与药学上可接受的酸的加成盐,含有该酸的药物可用作双重α2/ 5 -HT2c拮抗剂。
-
-
-
-
-
-
-
-
-